BACKGROUND: The therapeutic outcome and @entity137 of 3-D conformal photon external beam therapy of @entity263 is well documented in the literature. Progress is still in work for optimization of treatment strategies by risk-adapted dose escalation studies to improve @entity5 control without increase of radiation side effects. @entity1 AND METHODS: We present our experience of 291 @entity1 treated between January 1994 and August 1997 with a 3-D planned four-field box technique and a central dose of 66 Gy. Biochemical response of @entity1 with radiotherapy alone (group 1, n = 72 pts.) has been analyzed in detail. Acute radiation side effects are given for all @entity1 (n = 291), late radiation side effects are given for @entity1 treated between Jan 1994 and Jan 1996 with a median follow-up of 22 months (n = 115 pts.). RESULTS: We have observed a biochemical response (nadir PSA < 1 after 12 months, < 2 after 6 months) for @entity1 treated with radiotherapy alone without hormone manipulation in 67%. Incidence of late rectal and bladder morbidity (grade 2 and 3) was 9.4% and 4%, respectively. CONCLUSION: Compared to other reports our results indicate a high rate of @entity5 control (early biochemical response) and a low rate of late morbidity. Nevertheless, we will start a risk-adapted dose escalation study up to 74 Gy for unfavorable subgroups (G2-3, Gleason Score > 7, PSA > 10) to improve treatment outcome.

Three dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for XXXX : early results.

@entity5 :: ('MESH:D009369', 'Disease') :: ['local tumor'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']
@entity263 :: (MESH:D011471,Disease) :: ['prostate carcinoma']
